Free Trial

Harmony Biosciences (HRMY) Stock Price, News & Analysis

-0.53 (-1.77%)
(As of 05/28/2024 ET)
Today's Range
50-Day Range
52-Week Range
241,381 shs
Average Volume
385,958 shs
Market Capitalization
$1.67 billion
P/E Ratio
Dividend Yield
Price Target

Harmony Biosciences MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
38.1% Upside
$40.63 Price Target
Short Interest
23.14% of Float Sold Short
Dividend Strength
News Sentiment
0.70mentions of Harmony Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$389,536 Sold Last Quarter
Proj. Earnings Growth
From $2.53 to $3.87 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.88 out of 5 stars

Medical Sector

164th out of 931 stocks

Pharmaceutical Preparations Industry

66th out of 432 stocks

HRMY stock logo

About Harmony Biosciences Stock (NASDAQ:HRMY)

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

HRMY Stock Price History

HRMY Stock News Headlines

Key Takeaways From Harmony Biosciences Analyst Ratings
Harmony Biosciences earnings: here's what Wall Street expects
See More Headlines
Receive HRMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
8 Analysts


Net Income
$128.85 million
Pretax Margin


Sales & Book Value

Annual Sales
$582.02 million
Cash Flow
$2.56 per share
Book Value
$7.97 per share


Free Float
Market Cap
$1.67 billion
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Jeffrey S. Aronin (Age 56)
    Founder & Non-Executive Chairman
    Comp: $185.67k
  • Dr. Jeffrey M. Dayno M.D. (Age 67)
    President, CEO & Director
    Comp: $1.26M
  • Mr. Sandip S. Kapadia CPA (Age 54)
    M.B.A., Executive VP, Chief Administrative Officer & CFO
    Comp: $813.52k
  • Mr. David Bradshaw
    Head of Technical Operations
  • Luis Sanay
    Head of Investor Relations
  • Mr. Christian Ulrich
    General Counsel & Corporate Secretary
  • Ms. Tricia Glover
    Chief Compliance Officer
  • Ms. Audrey Murphy SPHR
    Vice Presidet of Human Resources
  • Ms. Cate McCanless
    Head of Corporate Affairs & Public Policy
  • Ms. Kelli Wright
    Senior Manager of Patient Advocacy & Harmony Biosciences

HRMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Harmony Biosciences stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Harmony Biosciences in the last twelve months. There are currently 2 sell ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" HRMY shares.
View HRMY analyst ratings
or view top-rated stocks.

What is Harmony Biosciences' stock price target for 2024?

8 analysts have issued 1 year price targets for Harmony Biosciences' stock. Their HRMY share price targets range from $27.00 to $59.00. On average, they anticipate the company's stock price to reach $40.63 in the next twelve months. This suggests a possible upside of 38.1% from the stock's current price.
View analysts price targets for HRMY
or view top-rated stocks among Wall Street analysts.

How have HRMY shares performed in 2024?

Harmony Biosciences' stock was trading at $32.30 on January 1st, 2024. Since then, HRMY shares have decreased by 8.9% and is now trading at $29.42.
View the best growth stocks for 2024 here

Are investors shorting Harmony Biosciences?

Harmony Biosciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 7,090,000 shares, an increase of 5.5% from the April 30th total of 6,720,000 shares. Based on an average daily trading volume, of 415,000 shares, the short-interest ratio is currently 17.1 days. Approximately 23.1% of the company's shares are short sold.
View Harmony Biosciences' Short Interest

When is Harmony Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 6th 2024.
View our HRMY earnings forecast

How were Harmony Biosciences' earnings last quarter?

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its quarterly earnings results on Tuesday, April, 30th. The company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.60 by $0.07. The firm earned $154.62 million during the quarter, compared to analysts' expectations of $154.10 million. Harmony Biosciences had a trailing twelve-month return on equity of 28.26% and a net margin of 22.30%. The firm's quarterly revenue was up 29.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.48 earnings per share.

What guidance has Harmony Biosciences issued on next quarter's earnings?

Harmony Biosciences updated its FY 2024 earnings guidance on Tuesday, April, 30th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $700.0 million-$720.0 million, compared to the consensus revenue estimate of $710.2 million.

What other stocks do shareholders of Harmony Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harmony Biosciences investors own include Advance Auto Parts (AAP), Advanced Micro Devices (AMD), Boeing (BA), Berry Global Group (BERY), Bunge Global (BG), Carrier Global (CARR), Commercial Metals (CMC), Canadian Solar (CSIQ), Deere & Company (DE) and Eastman Chemical (EMN).

When did Harmony Biosciences IPO?

Harmony Biosciences (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at a price of $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO.

Who are Harmony Biosciences' major shareholders?

Harmony Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (6.39%), LSV Asset Management (0.59%), Jacobs Levy Equity Management Inc. (0.42%), Capital Management Corp VA (0.37%), Principal Financial Group Inc. (0.34%) and Janus Henderson Group PLC (0.33%). Insiders that own company stock include Andreas Wicki, Jack Nielsen, Jeffrey Dierks, Jeffrey M Dayno, Jeffrey M Dayno, John C Jacobs and John C Jacobs.
View institutional ownership trends

How do I buy shares of Harmony Biosciences?

Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HRMY) was last updated on 5/29/2024 by Staff

From Our Partners